AMGEN Return on Equity

AMGEN (AMGN) currently reports a ROE of 74.8%. That is above the Healthcare sector average of 20.77%. Use the charts on this page to explore AMGEN's ROE history and peer comparisons.

AMGEN's ROE of 74.8% is higher than the Healthcare sector average of 20.77%. That is roughly 260.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but AMGEN's current 74.8% should be judged against Healthcare norms (sector average: 20.77%) and against AMGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 74.8%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for AMGEN, and consider following AMGN for alerts when major investors trade the stock.

AMGEN is classified in the Healthcare sector. On ROE, it currently shows 74.8% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMGN with unrelated industries.